Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1201 to 1215 of 1422 results for social care

  1. Aflibercept for treating diabetic macular oedema (TA346)

    Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by diabetic macular oedema in adults.

    Technology appraisal guidance
    Published
    22 July 2015
    View recommendations

    Sections for TA346

  2. Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)

    Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.

    Technology appraisal guidance
    Published
    22 June 2016
    View recommendations

    Sections for TA393

  3. Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA736)

    Evidence-based recommendations on nivolumab (Opdivo) for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy in adults.

    Technology appraisal guidance
    Published
    20 October 2021
    View recommendations

    Sections for TA736

  4. Alzheimer's disease (early) - gantenerumab [ID6142]

    In development [GID-TA11269] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)

    Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making

    Evidence summary
    Published
    2 December 2015

  6. Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]

    In development [GID-TA10467] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Venetoclax with ibrutinib and obinutuzumab for untreated chronic lymphocytic leukaemia ID1270

    Discontinued [GID-TA10211]

    Technology appraisal guidance
    Discontinued

  8. Nivolumab with ipilimumab for previously treated extensive stage small-cell lung cancer [ID1228]

    Discontinued [GID-TA10203]

    Technology appraisal guidance
    Discontinued

  9. Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma [ID3940]

    Discontinued [GID-TA10830]

    Technology appraisal guidance
    Discontinued

  10. The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)

    Discontinued [GID-MT517]

    Medical technologies guidance
    Discontinued

  11. Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]

    In development [GID-TA10405] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Baricitinib for treating active autoantibody-positive systemic lupus erythematosus [ID3997]

    Discontinued [GID-TA10892]

    Technology appraisal guidance
    Discontinued

  13. Ofatumumab (Arzerra) in combination with chemotherapy for follicular lymphoma; second line - refractory to rituximab [ID1487]

    Discontinued [GID-TA10437]

    Technology appraisal guidance
    Discontinued

  14. Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy [ID1147]

    Discontinued [GID-TA10343]

    Technology appraisal guidance
    Discontinued

  15. Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353

    Discontinued [GID-TA10320]

    Technology appraisal guidance
    Discontinued